Related Experiment Video

Updated: May 24, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

HER2+ breast cancer therapy: by CPP-ZFN mediated targeting of mTOR?

Rekha Puria1, Shakti Sahi, Vikrant Nain

  • 1School of Biotechnology, Gautam Buddha University, Greater NOIDA, Gautam Budh Nagar-201310, India. rpuria@gbu.ac.in

Technology in Cancer Research & Treatment
|February 17, 2012
PubMed

Insights

This study proposes a novel cancer therapy using cell-penetrating peptides (CPPs) linked to zinc-finger nucleases (ZFNs) to target the mTOR pathway in HER2+ cancers, overcoming drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • HER2+ cancers often develop resistance to therapies like trastuzumab.
  • This resistance is linked to hyperactivation of the PI3K/Akt/mTOR signaling pathway.
  • Current mTOR inhibitors face limitations like toxicity and acquired resistance.

Purpose of the Study:

  • To develop a novel therapeutic strategy targeting the mTOR pathway in HER2+ cancers.
  • To overcome existing limitations of current anti-cancer drug resistance.
  • To investigate the potential of a cell-penetrating peptide (CPP)-Zinc Finger Nuclease (ZFN) conjugate.

Main Methods:

  • Conjugating a HER2-specific CPP with an mTOR-specific ZFN.
  • Utilizing ZFNs for precise genome engineering to inactivate the mTOR locus.
  • Developing a targeted molecular intervention to inhibit the PI3K/Akt/mTOR pathway.

Main Results:

  • The proposed CPP-ZFN conjugate aims to specifically target and disable the mTOR gene in HER2+ cancer cells.
  • This approach is expected to inhibit the crucial PI3K/Akt/mTOR pathway, hindering cancer cell growth and proliferation.
  • The combination leverages established HER2-targeting CPPs and ZFN's genome-editing capabilities.

Conclusions:

  • The CPP-ZFN conjugate represents a promising novel therapeutic approach for HER2+ cancers resistant to current treatments.
  • This strategy offers a precise and potentially more effective way to inhibit the mTOR pathway.
  • The high success prospects are supported by existing research in CPPs and ZFN applications.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.